Drug costs and nocebo risks: Navigating the Humira ‘biosimilar boom’ 1 year later
The first Humira biosimilar hit the U.S. market a little over a year ago. Since then, a total of nine biosimilars for Humira (adalimumab, AbbVie) have launched, including two with interchangeable status. However, despite promises of greater competition and reduced prices, it remains to be seen, now a full year from the launch of Amjevita (adalimumab-atto, Amgen) in January 2023, what impact these drugs will — or can — have on the U.S. pharmaceutical market and drug pricing system.
